A small molecule inhibitor of NF-kappa B, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells
Publication in refereed journal

Times Cited
Web of Science34WOS source URL (as at 13/09/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractDespite the demonstrated constitutive activation of NF-kappa B in nasopharyngeal carcinoma (NPC), the therapeutic potential of targeting this pathway has not been investigated. Here, we employed a small molecule inhibitor of NF-kappa B, DHMEQ (which mainly blocks nuclear translocation of activated NF-kappa B) and demonstrated significant inhibition of NPC cell proliferation, migration, invasion, as well as anchorage-independent growth. These antitumor effects were associated with induction of G(2)/M cell cycle arrest and apoptosis, and down-regulation of NF-kappa B target genes (EGFR, cyclin D1 and survivin). This first demonstration of therapeutic benefits of NF-kappa B targeting in NPC implicates the importance of targeting this pathway in NPC. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
All Author(s) ListWong JHT, Lui VWY, Umezawa K, Ho Y, Wong EYL, Ng MHL, Cheng SH, Tsang CM, Tsao SW, Chan ATC
Journal nameCancer Letters
Detailed descriptionEpub ahead of print.
Volume Number287
Issue Number1
Pages23 - 32
LanguagesEnglish-United Kingdom
KeywordsAnti-invasion; Anti-proliferation; Apoptosis; DHMEQ; Nasopharyngeal carcinoma; NF-kappa B inhibitor
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2021-13-09 at 23:49